Patent Settlements: 2nd Circuit Okays Bayer's Cipro Deal But Doesn't Want To
Executive Summary
While the U.S. Court of Appeals for the Second Circuit found that a reverse settlement agreement involving Bayer's antibiotic Cipro did not violate antitrust laws, it invited the plaintiffs to seek a reexamination of the case by the full court
You may also be interested in...
Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.
Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.
Supreme Court To Hear Generic Drug Preemption Cases Against Advice Of Solicitor General
The court agreed to review three cases in which generic manufacturers of Reglan (metoclopramide) were held responsible for warning about the risk of tardive dyskinesia.